proposed that targeting vesicle trafficking-related protein myoferlin could be a promising opportunity to treat CRC clinically, as myoferlin suppressed exosome secretion and internalization and thereby reduced the invasive capacity of tumor cells (187). This evidence concerns the gene MYOF and neoplasm.